Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000893220-95-000896
Filing Date
1995-12-20
Accepted
1995-12-20 00:00:00
Documents
12
Period of Report
1995-09-30
SROs
NONE

Document Format Files

Seq Description Document Type Size
1 FORM 10-K FOR THE PERIOD ENDING SEPTEMBER 30, 1995 10-K 130711
2 CERTIFICATE OF INCORPORATION, AS AMENDED EX-3.1 37618
3 BY-LAWS EX-3.2 21420
4 OSI ROYALTY FREE LICENSE AGREEMENT EX-10.19 2893
5 PFIZER ROYALTY FREE LICENSE AGREEMENT EX-10.20 2577
6 ROYALTY AGREEMENT BETWEEN THE COMPANY AND PFIZER EX-10.21 25147
7 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT EX-10.27 65742
8 LETTER AGREEMENT EX-10.28 3994
9 REGISTRATION RIGHTS AGREEMENT EX-10.29 12300
10 SUBSIDIARIES OF THE COMPANY EX-21 204
11 CONSENT OF KPMG PEAT MARWICK LLP EX-23 913
12 FINANCIAL DATA SCHEDULE EX-27 2057
  Complete submission text file 0000893220-95-000896.txt   308260
Mailing Address 106 CHARLES LINDBERGH BLVD UNIONDALE NY 11553-3649
Business Address 106 CHARLES LINDBERGH BLVD UNIONDALE NY 11553 5162220023
ONCOGENE SCIENCE INC (Filer) CIK: 0000729922 (see all company filings)

EIN.: 133159796 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-K | Act: 34 | File No.: 000-15190 | Film No.: 95603148
SIC: 2835 In Vitro & In Vivo Diagnostic Substances